Download PDF
Psychiatr Prax 2006; 33: 47-54
DOI: 10.1055/s-2005-867026
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Rezidivprophylaxe bipolarer Erkrankungen

Prophylaxis of Bipolar DisorderAndrea  Sterr1 , Benedikt  Amann1 , Heinz  Grunze1
  • 1Psychiatrische Universitätsklinik der LMU München
Further Information

Publication History

Publication Date:
01 March 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Bis vor einigen Jahren hat sich die medikamentöse Behandlung zur Verhinderung von Rückfällen bei bipolaren Erkrankungen in erster Linie auf Lithium beschränkt, das sich vor allem bei den typischen, klassischen Verläufen der bipolaren Störungen mit seiner stimmungsstabilisierenden Wirkung und antisuizidalem Effekt günstig auf den Krankheitsverlauf auswirkt. Bei atypischen Symptomen oder schnellem Phasenwechsel jedoch scheint die Effektivität eingeschränkt, mit der Konsequenz, dass weitere Therapieoptionen, v. a. Antiepileptika wie Carbamazepin, Valproat oder Lamotrigin auch in der Indikation der prophylaktischen Anwendung untersucht wurden. Auch atypische Neuroleptika, Schilddrüsenhormone und Omega-Fettsäuren wurden in Langzeitstudien bezüglich stimmungsstabilisierender Effekte untersucht. Der vorliegende Artikel fasst den gegenwärtigen Stand zur Wirksamkeit der verschiedenen Therapieoptionen in der Langzeittherapie zusammen.

Abstract

Until recently, the psychopharmacological treatment alternatives for bipolar maintenance treatment were limited to lithium, which seems of special usefulness in a classical manifestation of the illness with mood-stabilising and anti-suicidal properties. With atypical features like psychotic symptoms or rapid cycling, lithium seems to be less useful. This led to further research into alternative options as carbamazepine, valproate or lamotrigine as well as atypical neuroleptics, thyroid hormones or innovative substances like omega fatty acids. This article summarises the current state of knowledge on treatment options for maintenance therapy.

Literatur

  • 1 American Psychiatric Association . Practice guideline for the treatment of patients with bipolar disorder. American Psychiatric Association.  Am J Psychiatry. 1994;  151 (12 Suppl) 1-36
    PubMedGoogle Scholar
  • 2 Bourgeois M L, Hantouche E G, Akiskal H S. The Epiman and Epidep french studies of bipolarity.  Journal of Bipolar Disorder. 1997;  1 (1) 13-19
    PubMedGoogle Scholar
  • 3 Angst J. Epidemiologie du spectre bipolaire.  Encephale. 1995;  21 37-42
    PubMedGoogle Scholar
  • 4 Baastrup P C, Schou M. Lithium as a prophylactic agents. Its effect against recurrent depressions and manic-depressive psychosis.  Arch Gen Psychiatry. 1967;  16 (2) 162-172
    PubMedGoogle Scholar
  • 5 Walden J, Grunze H. Bipolare affektive Störungen - Ursachen und Behandlung. 3 ed. Stuttgart, New York; Thieme 2003
    Google Scholar
  • 6 Bowden C L. Efficacy of lithium in mania and maintenance therapy of bipolar disorder.  J Clin Psychiatry. 2000;  61, Suppl 9 35-40
    PubMedGoogle Scholar
  • 7 Calabrese J R, Fatemi S H, Kujawa M, Woyshville M J. Predictors of response to mood stabilizers.  J Clin Psychopharmacol. 1996;  16 (2, Suppl 1) 24-31
    PubMedGoogle Scholar
  • 8 Calabrese J R, Shelton M D, Rapport D J, Youngstrom E A, Shirley E, Elhaj O. et al . A 20-month, double-blind, maintenance study of lithium versus divalproex monotherapy in bipolar I and II disorder accompanied by rapid cycling.  Eur Neuropsychopharmacol. 2003;  23, Suppl 4 227
    PubMedGoogle Scholar
  • 9 Greil W, Ludwig-Mayerhofer W, Erazo N, Schöchlin C, Schmidt S, Engel R R. et al . Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a randomised study.  J Affect Disord. 1997;  43 (2) 151-161
    CrossrefPubMedGoogle Scholar
  • 10 Hartong E G, Moleman P, Hoogduin C A, Broekman T G, Nolen W A. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients.  J Clin Psychiatry. 2003;  64 (2) 144-151
    CrossrefPubMedGoogle Scholar
  • 11 Bowden C L, Calabrese J R, McElroy S L, Gyulai L, Wassef A, Petty F. et al . A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.  Arch Gen Psychiatry. 2000;  57 481-489
    CrossrefPubMedGoogle Scholar
  • 12 Bowden C L, Calabrese J R, Sachs G, Yatham L N, Asghar S A, Hompland M. et al . A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder.  Arch Gen Psychiatry. 2003;  60 (4) 392-400
    CrossrefPubMedGoogle Scholar
  • 13 Calabrese J, Bowden C L, Sachs G, Yatham L N, Behnke K, Mehtonen O-P. et al . A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients with Bipolar I Disorder.  J Clin Psychiatry. 2003;  64 (1013) 1024
    PubMedGoogle Scholar
  • 14 Calabrese J R, Suppes T, Bowden C L, Sachs G S, Swann A C, McElroy S L. et al . A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group.  J Clin Psychiatry. 2000;  61 (11) 841-850
    Google Scholar
  • 15 Suppes T, Webb A, Paul B, Carmody T, Kraemer H, Rush A J. Clinical outcome in a randomized 1-year trial of clozapine versus treatment as usual for patients with treatment-resistant illness and a history of mania.  Am J Psychiatry. 1999;  156 (8) 1164-1169
    PubMedGoogle Scholar
  • 16 Vieta E, Goikolea J M, Corbella B, Benabarre A, Reinares M, Martinez G. et al . Risperidone safety and efficacy in the treatment of bipolar and schizoaffective disorders: results from a 6-month, multicenter, open study.  J Clin Psychiatry. 2001;  62 (10) 818-825
    PubMedGoogle Scholar
  • 17 Tohen M, Ketter T A, Zarate C A, Suppes T, Frye M, Altshuler L. et al . Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.  Am J Psychiatry. 2003;  160 (7) 1263-1271
    CrossrefPubMedGoogle Scholar
  • 18 Tohen M, Chengappa K N, Suppes T, Baker R W, Zarate C A, Bowden C L. et al . Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone.  Br J Psychiatry. 2004;  184 337-345
    CrossrefPubMedGoogle Scholar
  • 19 Tohen M, Marneros A, Greil W, Koukopoulos A, Calabrese J R, Bowden C. et al .Olanzapine versus Lithium in Relapse/Recurrence Prevention in Bipolar Disorder: A Randomized Double-blind Controlled 12-month Clinical Trial. Am J Psychiatry in press
    Google Scholar
  • 20 Tohen M, Bowden C, Calabrese J, Chou J C, Baker R W, Williamson D. et al . Olanzapine's efficacy for relapse prevention in bipolar disorder: A randomized double-blind controlled 12-month clinical trial.  World J Biol Psychiatry. 2004;  5, suppl 1 51
    PubMedGoogle Scholar
  • 21 Bauer M, Hellweg R, Baumgartner A. Hochdosierte Thyroxinbehandlung bei therapie- und prophylaxeresistenten Patienten mit affektiven Psychosen.  Nervenarzt. 1998;  69 (11) 1019-1022
    CrossrefPubMedGoogle Scholar
  • 22 Stoll A L, Severus W E, Freeman M P, Rueter S, Zboyan H A, Diamond E. et al . Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial.  Arch Gen Psychiatry. 1999;  56 (5) 407-412
    PubMedGoogle Scholar
  • 23 Keck P, Mintz J, McElroy S, Freeman M P, Suppes T, Frye M. et al .Double-Blind, Randomized, Placebo-Controlled Trials of Ethyl-Eicosapentanoate in the Treatment of Bipolar Depression and Rapid Cycling Bipolar Disorder. Am J Psychiatry in press
    Google Scholar
  • 24 Grunze H, Walden J, Dittmann S, Berger M, Bergmann A, Bräunig P. et al . Psychopharmakotherapie Bipolarer Affektiver Erkrankungen.  Nervenarzt. 2002;  73 4-17
    CrossrefPubMedGoogle Scholar
  • 25 Johnson R E, McFarland B H. Lithium use and discontinuation in a health maintenance organization.  Am J Psychiatry. 1996;  153 (8) 993-1000
    PubMedGoogle Scholar
  • 26 Scott J, Pope M. Self-reported adherence to treatment with mood stabilizers, plasma levels, and psychiatric hospitalization.  Am J Psychiatry. 2002;  159 (11) 1927-1929
    CrossrefPubMedGoogle Scholar
  • 27 Miklowitz D J, Frank E, George E L. New psychosocial treatments for the outpatient management of bipolar disorder.  Psychopharmacol Bull. 1996;  32 (4) 613-621
    PubMedGoogle Scholar
  • 28 Swartz H A, Frank E. Psychotherapy for bipolar depression: a phase-specific treatment strategy?.  Bipolar Disord. 2001;  3 (1) 11-22
    CrossrefPubMedGoogle Scholar
  • 29 Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea J M, Benabarre A. et al . A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission.  Arch Gen Psychiatry. 2003;  60 (4) 402-407
    CrossrefPubMedGoogle Scholar
  • 30 Keller M B, Lavori P W, Coryell W, Endicott J, Mueller T I. Bipolar I: a five-year prospective follow-up.  J Nerv Ment Dis. 1993;  181 (4) 238-245
    PubMedGoogle Scholar
  • 31 Goodwin F K, Ghaemi S N. Understanding manic-depressive illness.  Arch Gen Psychiatry. 1998;  55 (1) 23-25
    PubMedGoogle Scholar
  • 32 Möller H-J, Grunze H. Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review. Eur Arch Psychiatry Clin Neurosci in press
    Google Scholar
  • 33 Altshuler L, Suppes T, Black D, Nolen W A, Keck Jr P E, Frye M A. et al . Impact of antidepressant discontinuation after acute bipolar depression remission on rates of depressive relapse at 1-year follow-up.  Am J Psychiatry. 2003;  160 (7) 1252-1262
    CrossrefPubMedGoogle Scholar
  • 34 Sachs G S, Printz D J, Kahn D A, Carpenter D, Docherty J P. The Expert Consensus Guideline Series: Medication Treatment of Bipolar Disorder 2000.  Postgrad Med Spec Report. 2000;  1-104
    PubMedGoogle Scholar
  • 35 Nolen W A, Knoppert-van der Klein E AM, Bouvy P F, Honig A, Klompenhouwer J L, Wit A De. et al .Richtlijn bipolaire stoornissen. Amsterdam; Boom 2001
    Google Scholar
  • 36 Grunze H, Kasper S, Goodwin G, Bowden C L, Möller H-J. WFSBP Task Force on Treatment Guidelines for Bipolar Disorders . The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders. Part III: Maintenance treatment.  World J Biol Psychiatry. 2004;  5 120-135
    CrossrefPubMedGoogle Scholar
  • 37 Prien R F, Caffey E M. Lithium prophylaxis: a critical review.  Compr Psychiatry. 1974;  15 (5) 257-263
    CrossrefPubMedGoogle Scholar
  • 38 Bowden C L, Lecrubier Y, Bauer M, Goodwin G, Greil W, Sachs G. et al . Maintenance therapies for classic and other forms of bipolar disorder.  J Affect Disord. 2000;  59, Suppl 1 57-67
    CrossrefPubMedGoogle Scholar
  • 39 Bowden C L, Singh V. Valproate in bipolar disorder: 2000 onwards.  Acta Psychiatr Scand Suppl. 2005;  (426) 13-20
    CrossrefPubMedGoogle Scholar
  • 40 Gelenberg A J, Kane J M, Keller M B, Lavori P, Rosenbaum J F, Cole K. et al . Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder.  N Engl J Med. 1989;  321 (22) 1489-1493
    PubMedGoogle Scholar
  • 41 Kleindienst N, Greil W. Lithium in the long-term treatment of bipolar disorders.  Eur Arch Psychiatry Clin Neurosci. 2003;  253 (3) 120-125
    CrossrefPubMedGoogle Scholar
  • 42 VanValkenburg C, Kluznik J, Merrill R, Erickson W. Therapeutic levels of valproate for psychosis.  Psychopharmacol Bull. 1990;  26 (2) 254-255
    PubMedGoogle Scholar
  • 43 Bowden C L, Janicak P G, Orsulak P, Swann A C, Davis J M, Calabrese J R. et al . Relation of serum valproate concentration to response in mania.  Am J Psychiatry. 1996;  153 (6) 765-770
    PubMedGoogle Scholar
  • 44 Geddes J R, Burgess S, Hawton K, Jamison K, Goodwin G M. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials.  Am J Psychiatry. 2004;  161 (2) 217-222
    CrossrefPubMedGoogle Scholar
  • 45 Maj M, Pirozzi R, Magliano L, Bartoli L. Long-term outcome of lithium prophylaxis in bipolar disorder: a 5-year prospective study of 402 patients at a lithium clinic.  Am J Psychiatry. 1998;  155 (1) 30-35
    PubMedGoogle Scholar
  • 46 Gitlin M J, Swendsen J, Heller T L, Hammen C. Relapse and impairment in bipolar disorder.  Am J Psychiatry. 1995;  152 (11) 1635-1640
    PubMedGoogle Scholar
  • 47 Greil W, Kleindienst N, Schlösser S. Medikamentöse Rezidivprohylaxe affektiver Störungen. In: Möller H-J (Hrsg) Therapie psychiatrischer Erkrankungen. Stuttgart; Enke 1999: 424-450
    Google Scholar
  • 48 Goodwin F K, Jamison K R. Manic-depressive illness. New York; Oxford University Press 1990
    Google Scholar
  • 49 Dunner D L, Fieve R R. Clinical factors in lithium carbonate prophylaxis failure.  Arch Gen Psychiatry. 1974;  30 (2) 229-233
    CrossrefPubMedGoogle Scholar
  • 50 Calabrese J R, Rapport D J, Youngstrom E A, Jackson K, Bilali S, Findling R L. New data on the use of lithium, divalproate, and lamotrigine in rapid cycling bipolar disorder.  Eur Psychiatry. 2005;  20 (2) 92-95
    CrossrefPubMedGoogle Scholar
  • 51 Thies-Flechtner K, Müller-Oerlinghausen B, Seibert W, Walther A, Greil W. Effect of prophylactic treatment on suicide risk in patients with major affective disorders. Data from a randomized prospective trial.  Pharmacopsychiatry. 1996;  29 (3) 103-107
    Google Scholar
  • 52 Ahrens B, Müller-Oerlinghausen B. Die antisuizidale und mortalitätssinkende Wirkung von Lithium. In: Müller-Oerlinghausen B, Greil W, Berghöfer A (Hrsg) Die Lithiumtherapie: Nutzen, Risiken, Alternativen. Berlin, Heidelberg; Springer 1997: 262-277
    Google Scholar
  • 53 Schou M. The early European lithium studies.  Aust N Z J Psychiatry. 1999;  33, Suppl 39-47
    PubMedGoogle Scholar
  • 54 Tondo L, Jamison K R, Baldessarini R J. Effect of lithium maintenance on suicidal behavior in major mood disorders.  Ann N Y Acad Sci. 1997;  836 339-351
    PubMedGoogle Scholar
  • 55 Johnston A M, Eagles J M. Lithium-associated clinical hypothyroidism. Prevalence and risk factors.  Br J Psychiatry. 1999;  175 336-339
    PubMedGoogle Scholar
  • 56 Kulhara P, Basu D, Mattoo S K, Sharan P, Chopra R. Lithium prophylaxis of recurrent bipolar affective disorder: long-term outcome and its psychosocial correlates.  J Affect Disord. 1999;  54 (1 - 2) 87-96
    CrossrefPubMedGoogle Scholar
  • 57 Grunze H. Carbamazepine, other anticonvulsants, antidepressants and augmenting agents. In: Akiskal H, Tohen M (eds) Bipolar Psychopharmacotherapy. Chichester; John Wiley 2005: 63-82
    Google Scholar
  • 58 Greil W, Kleindienst N, Erazo N, Müller-Oerlinghausen B. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder.  J Clin Psychopharmacol. 1998;  18 455-460
    CrossrefPubMedGoogle Scholar
  • 59 Hesslinger B, Normann C, Langosch J M, Klose P, Berger M, Walden J. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients.  J Clin Psychopharmacol. 1999;  19 (4) 310-315
    CrossrefPubMedGoogle Scholar
  • 60 Spina E, Pisani F, Perucca E. Clinically significant pharmacokinetic drug interactions with carbamazepine. An update.  Clin Pharmacokinet. 1996;  31 (3) 198-214
    CrossrefPubMedGoogle Scholar
  • 61 Grunze H, Walden J. Relevance of new and newly rediscovered anticonvulsants for atypical forms of bipolar disorder.  J Affect Disord. 2002;  72, Suppl 1 15-21
    CrossrefPubMedGoogle Scholar
  • 62 Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance.  Epilepsia. 1994;  35, Suppl 3 14-19
    PubMedGoogle Scholar
  • 63 Gram L. Clinical experience with oxcarbazepine.  Epilepsia. 1994;  35, Suppl 3 21-22
    PubMedGoogle Scholar
  • 64 Amelsvoort T Van, Bakshi R, Devaux C B, Schwabe S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review.  Epilepsia. 1994;  35 (1) 181-188
    PubMedGoogle Scholar
  • 65 Brennan M J, Sandyk R, Borsook D. Use of Sodium Valproate in the Management of Affective Disorders: Basic and Clinical Aspects. In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants In Affective Disorders. Amsterdam, Oxford, Princeton; Elsevier Science Publishers B. V. EXCERPTA MEDICA, International Congress Series 1984: 56-65
    Google Scholar
  • 66 Lambert P A. Acute and prophylactic therapies of patients with affective disorders using valpromide (dipropylacetamide). In: Emrich HM, Okuma T, Müller AA (eds) Anticonvulsants in affective disorders. Amsterdam, Oxford, Princeton; Elsevier Science Publishers 1984: 33-44
    Google Scholar
  • 67 Solomon D A, Keitner G I, Ryan C E, Miller I W. Lithium plus valproate as maintenance polypharmacy for patients with bipolar I disorder: a review.  J Clin Psychopharmacol. 1998;  18 (1) 38-49
    CrossrefPubMedGoogle Scholar
  • 68 Denicoff K D, Smith-Jackson E E, Bryan A L, Ali S O, Post R M. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder.  Am J Psychiatry. 1997;  154 (10) 1456-1458
    PubMedGoogle Scholar
  • 69 Macritchie K A, Geddes J R, Scott J, Haslam D R, Goodwin G M. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Cochrane Database Syst Rev 2001 (3) CD003196
    Google Scholar
  • 70 Bowden C. The effectiveness of divalproate in all forms of mania and the broader bipolar spectrum: many questions, few answers.  J Affect Disord. 2004;  79, Suppl 1 S9-14
    CrossrefPubMedGoogle Scholar
  • 71 Rottach K G, Weiss-Brummer J, Wieland U, Schmauss M. Valproinsäure als Phasenprophylaktikum - Ein Fall von Valproat-Enzephalopathie.  Nervenarzt. 2000;  71 401-403
    CrossrefPubMedGoogle Scholar
  • 72 Rasgon N L, Altshuler L L, Fairbanks L, Elman S, Bitran J, Labarca R. et al . Reproductive function and risk for PCOS in women treated for bipolar disorder.  Bipolar Disord. 2005;  7 (3) 246-259
    CrossrefPubMedGoogle Scholar
  • 73 Calabrese J R, Rapport D J, Kimmel S E, Reece B, Woyshville M J. Rapid cycling bipolar disorder and its treatment with valproate.  Can J Psychiatry. 1993;  38 (3, Suppl 2) 57-61
    PubMedGoogle Scholar
  • 74 Swann A C, Bowden C L, Morris D, Calabrese J R, Petty F, Small J. et al . Depression during mania. Treatment response to lithium or divalproex.  Arch Gen Psychiatry. 1997;  54 (1) 37-42
    CrossrefPubMedGoogle Scholar
  • 75 McElroy S L, Keck P E, Stanton S P, Tugrul K C, Bennett J A, Strakowski S M. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.  J Clin Psychiatry. 1996;  57 (4) 142-146
    PubMedGoogle Scholar
  • 76 Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.  Psychopharmacology Berl. 2000;  150 (1) 15-23
    CrossrefPubMedGoogle Scholar
  • 77 Goodwin G M, Bowden C L, Calabrese J R, Grunze H, Kasper S, White R. et al . A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder.  J Clin Psychiatry. 2004;  65 (3) 432-441
    CrossrefPubMedGoogle Scholar
  • 78 Calabrese J R, Bowden C L, Sachs G S, Ascher J A, Monaghan E, Rudd G. et al . A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression.  J Clin Psychiatry. 1999;  60 79-88
    CrossrefPubMedGoogle Scholar
  • 79 Banov M D, Zarate Jr C A, Tohen M, Scialabba D, Wines Jr J D, Kolbrener M. et al . Clozapine therapy in refractory affective disorders: polarity predicts response in long-term follow-up.  J Clin Psychiatry. 1994;  55 (7) 295-300
    PubMedGoogle Scholar
  • 80 Calabrese J R, Meltzer H Y, Markovitz P J. Clozapine prophylaxis in rapid cycling bipolar disorder.  J Clin Psychopharmacol. 1991;  11 (6) 396-397
    PubMedGoogle Scholar
  • 81 Puri B K, Taylor D G, Alcock M E. Low-dose maintenance clozapine treatment in the prophylaxis of bipolar affective disorder.  Br J Clin Pract. 1995;  49 (6) 333-334
    PubMedGoogle Scholar
  • 82 Hummel B, Dittmann S, Forsthoff A, Matzner N, Amann B, Grunze H. Clozapine as add-on medication in the maintenance treatment of bipolar and schizoaffective disorders: a case series.  Neuropsychobiology. 2002;  45, Suppl 1 37-42
    PubMedGoogle Scholar
  • 83 Cohen D. Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature.  Pharmacopsychiatry. 2004;  37 (1) 1-11
    Article in Thieme ConnectPubMedGoogle Scholar
  • 84 Seung Kim H F, Weeber E J, Sweatt J D, Stoll A L, Marangell L. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro.  Mol Psychiatry. 2001;  6 246-248
    CrossrefPubMedGoogle Scholar
  • 85 Severus W E, Ahrens B. Omega-3-Fettsäuren in der Psychiatrie.  Nervenarzt. 2000;  71 58-62
    CrossrefPubMedGoogle Scholar
  • 86 Frangou S, Lewis M. The Maudsley Bipolar Disorder Project: a double-blind, randomized, placebo-controlled trial of Ethyl-EPA as an adjunct treatment of depression in bipolar disorder.  Bipolar Disord. 2002;  4, suppl 1 123
    PubMedGoogle Scholar
  • 87 Leverich G, Altshuler L, Frye M, Suppes T, McElroy S, Keck P. et al .Antidepressant Augmentation in Bipolar Depression: A Higher Ratio of Full Switches to Subthreshold Hypomanias on Venlafaxine than Sertraline or Bupropion in Acute and Continuation Trials. Am J Psychiatry in press
    Google Scholar
  • 88 Wehr T A, Goodwin F K. Rapid cycling in manic-depressives induced by tricyclic antidepressants.  Arch Gen Psychiatry. 1979;  36 (5) 555-559
    PubMedGoogle Scholar
  • 89 Tondo L, Laddomada P, Serra G, Minnai G, Kukopulos A. Rapid cyclers and antidepressants.  Int Pharmacopsychiatry. 1981;  16 (2) 119-123
    PubMedGoogle Scholar
  • 90 Altshuler L L, Post R M, Leverich G S, Mikalauskas K, Rosoff A, Ackerman L. Antidepressant-induced mania and cycle acceleration: a controversy revisited.  Am J Psychiatry. 1995;  152 (8) 1130-1138
    PubMedGoogle Scholar
  • 91 Vieta E, Martínez-Arán A, Colom F, Benabarre A, Reinares M, Gastó C. Treatment of bipolar depression: paroxetine vs. venlafaxine.  Int J Neuropsychopharmacol. 2000;  3, Suppl 1 336-337
    PubMedGoogle Scholar
  • 92 Walden J, Schaerer L O, Schlösser S, Grunze H. An open longitidinal study of patients with bipolar rapid cycling treated with lithium or lamotrigine for mood stabilzation.  Bipolar disorders. 2000;  2 336-339
    CrossrefPubMedGoogle Scholar
  • 93 Abou-Saleh M T, Coppen A. Who responds to prophylactic lithium?.  J Affect Disord. 1986;  10 (2) 115-125
    CrossrefPubMedGoogle Scholar
  • 94 Maj M. Clinical prediction of response to lithium prophylaxis in bipolar patients: the importance of the previous pattern of course of the illness.  Clin Neuropharmacol. 1990;  13, Suppl 1 66-70
    PubMedGoogle Scholar
  • 95 Tondo L, Baldessarini R J. Rapid cycling in women and men with bipolar manic-depressive disorders.  Am J Psychiatry. 1998;  155 (10) 1434-1436
    PubMedGoogle Scholar
  • 96 Okuma T, Kishimoto A, Inoue K, Matsumoto H, Ogura A. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis. A preliminary report.  Folia Psychiatr Neurol Jpn. 1973;  27 (4) 283-297
    PubMedGoogle Scholar
  • 97 Fujiwara Y, Honda T, Tanaka Y, Aoki S, Kuroda S. Comparison of early- and late-onset rapid cycling affective disorders: clinical course and response to pharmacotherapy.  J Clin Psychopharmacol. 1998;  18 (4) 282-288
    CrossrefPubMedGoogle Scholar
  • 98 Okuma T. Effects of carbamazepine and lithium on affective disorders.  Neuropsychobiology. 1993;  27 (3) 138-145
    PubMedGoogle Scholar
  • 99 Joyce P R. Carbamazepine in rapid cycling bipolar affective disorder.  Int Clin Psychopharmacol. 1988;  3 (2) 123-129
    PubMedGoogle Scholar
  • 100 Pazzaglia P, Post R M, Ketter T A, Callahan A M, Marangell L B, Frye M A. et al . Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness.  J Clin Psychopharmacol. 1998;  18 (5) 404-413
    CrossrefPubMedGoogle Scholar
  • 101 Bauer M S, Whybrow P C. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study.  Arch Gen Psychiatry. 1990;  47 (5) 435-440
    CrossrefPubMedGoogle Scholar
  • 102 Post R M, Ketter T A, Pazzaglia P J, Denicoff K, George M S, Callahan A. et al . Rational polypharmacy in the bipolar affective disorders.  Epilepsy Res. 1996;  11, Suppl 153-180
    PubMedGoogle Scholar
  • 103 Frye M A, Ketter T A, Leverich G S, Huggins T, Lantz C, Denicoff K D. et al . The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study.  J Clin Psychiatry. 2000;  61 (1) 9-15
    PubMedGoogle Scholar
  • 104 Solomon D A, Ryan C E, Keitner G I, Miller I W, Shea M T, Kazim A. et al . A pilot study of lithium carbonate plus divalproex sodium for the continuation and maintenance treatment of patients with bipolar I disorder.  J Clin Psychiatry. 1997;  58 (3) 95-99
    PubMedGoogle Scholar
  • 105 Baethge C, Baldessarini R J, Mathiske-Schmidt K, Hennen J, Berghofer A, Muller-Oerlinghausen B. et al . Long-term combination therapy versus monotherapy with lithium and carbamazepine in 46 bipolar I patients.  J Clin Psychiatry. 2005;  66 (2) 174-182
    CrossrefPubMedGoogle Scholar
  • 106 Denicoff K D, Smith-Jackson E E, Disney E R, Ali S O, Leverich G S, Post R M. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder.  J Clin Psychiatry. 1997;  58 (11) 470-478
    PubMedGoogle Scholar
  • 107 Greil W, Ludwig-Mayerhofer W, Erazo N, Engel R R, Czernik A, Giedke H. et al . Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: a randomised study.  Eur Arch Psychiatry Clin Neurosci. 1997;  247 (1) 42-50
    PubMedGoogle Scholar
  • 108 Ciapparelli A, Dell'Osso L, Pini S, Chiavacci M C, Fenzi M, Cassano G B. Clozapine for treatment-refractory schizophrenia, schizoaffective disorder, and psychotic bipolar disorder: a 24-month naturalistic study.  J Clin Psychiatry. 2000;  61 (5) 329-334
    PubMedGoogle Scholar
  • 109 Basco M R, Rush A J. Cognitive Behavioral Therapy for Bipolar Disorder. New York; Guildford Press 1996
    Google Scholar
  • 110 Leverich G S, Post R M. Life charting the course of bipolar disorder.  Current review of Mood & Anxiety disorders. 1996;  1 48-61
    PubMedGoogle Scholar

Dr. med. Heinz Grunze

Psychiatrische Klinik der LMU

Nussbaumstraße 7

80336 München

Email: Heinz.Grunze@med.uni-muenchen.de